Related Experiment Videos
Piroxicam treatment protects mice from lethal pulmonary challenge with Pseudomonas aeruginosa
D O Sordelli1, M C Cerquetti, P A Fontán
1Instituto de Investigaciones Hematológicas, Academia Nacional de Medicine, de Buenos Aires, Argentina.
Abstract:
The effect of treatment with the nonsteroidal anti-inflammatory agent piroxicam on leukocyte migration to the lungs was investigated after aerosol administration of sublethal doses of Pseudomonas aeruginosa to mice. Piroxicam decreased, in a dose-related fashion, the polymorphonuclear leukocyte recruitment to, and the degree of perivascular and peribronchial infiltration in, the lungs. Piroxicam treatment also protected the animals in a dose-dependent manner from challenge with lethal doses of P. aeruginosa. The effect of piroxicam was not related to direct action of the drug on the microorganisms. Piroxicam treatment maintained the animal's pulmonary defenses against infection while diminishing inflammatory responses against P. aeruginosa, an occurrence decreasing the potential for tissue damage due to phagocytes migrating from circulation.
Insights
Piroxicam, a nonsteroidal anti-inflammatory drug, reduced lung inflammation and protected mice against Pseudomonas aeruginosa infection. This anti-inflammatory effect diminished tissue damage without directly harming the bacteria.
Area of Science:
- Immunology
- Pharmacology
- Microbiology
Background:
- Pseudomonas aeruginosa infections can cause significant lung inflammation and tissue damage.
- Nonsteroidal anti-inflammatory drugs (NSAIDs) like piroxicam are known to modulate inflammatory responses.
Purpose of the Study:
- To investigate the effect of piroxicam on leukocyte migration to the lungs during Pseudomonas aeruginosa infection.
- To determine if piroxicam provides protection against lethal P. aeruginosa challenge.
Main Methods:
- Mice were exposed to aerosolized sublethal doses of Pseudomonas aeruginosa.
- Piroxicam was administered in a dose-related manner.
- Leukocyte migration, inflammatory infiltration, and animal survival were assessed.
Main Results:
- Piroxicam significantly decreased polymorphonuclear leukocyte recruitment to the lungs in a dose-dependent manner.
- The drug reduced perivascular and peribronchial infiltration in the lungs.
- Piroxicam treatment dose-dependently protected mice against lethal P. aeruginosa challenge.
- Piroxicam's protective effect was not due to direct antimicrobial activity.
Conclusions:
- Piroxicam mitigates lung inflammation and enhances survival during P. aeruginosa infection by modulating inflammatory cell migration.
- The drug preserves pulmonary defenses while reducing inflammatory tissue damage caused by phagocyte infiltration.